Journals / Abant Tıp Dergisi / 2026 / Cilt: 15 Sayı: 2

Prognostic Value of Baseline Serum 25-Hydroxyvitamin D in High-Risk Resected Cutaneous Melanoma

Omer Ekin(Private Practice, Ankara, Türkiye)0000-0002-9977-5150
Osman Butun(Department of Medical Oncology, Acibadem Izmir Kent Hospital, Izmir, Türkiye)0000-0002-8559-472X
Rezan Berkay İzgör(DOKUZ EYLÜL ÜNİVERSİTESİ)
Oktay Halit Aktepe(DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-3540-0701
Pages
165–173
Publication Date
2026-08-28
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Prospective validation is warranted.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Vitamin D has been proposed as a potential prognostic biomarker in melanoma, but its significance in the postoperative setting remains unclear.
📊
Key Findings & Data:This study investigated the association between baseline serum 25-hydroxyvitamin D [25(OH)D] levels and relapse-free survival (RFS) in patients with completely resected stage II–III cutaneous melanoma.
💡
Conclusion & Impact:Prospective validation is warranted.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Cutaneous melanoma · High-risk resected melanoma · Prognostic biomarker

Abstract

Objective: Vitamin D has been proposed as a potential prognostic biomarker in melanoma, but its significance in the postoperative setting remains unclear. This study investigated the association between baseline serum 25-hydroxyvitamin D [25(OH)D] levels and relapse-free survival (RFS) in patients with completely resected stage II–III cutaneous melanoma. Materials and Methods: In this retrospective multicenter study, 154 patients with resected cutaneous melanoma and available baseline serum 25(OH)D measurements obtained within 3 months before or after surgery were included. Patients were categorized as having low (≤20 ng/mL) or high (>20 ng/mL) vitamin D levels. Associations between clinicopathologic variables and vitamin D status were examined, and RFS was assessed using Kaplan–Meier analysis and Cox proportional hazards regression models. Results: Of the 154 patients, 81 (58.5%) had low and 73 (41.5%) had high vitamin D levels. The median follow-up was 65 months, during which 67 relapse events occurred. Median RFS was 54.1 months (95% CI, 35.2–73.0) in the low vitamin D group and 89.2 months (95% CI, 68.3–110.2) in the high vitamin D group (p < 0.001). In univariable Cox analysis, stage III disease (HR, 3.30; 95% CI, 1.84–5.90; p < 0.001), absence of adjuvant therapy (HR, 1.98; 95% CI, 1.21–3.23; p = 0.006), low vitamin D level (HR, 2.68; 95% CI, 1.59–4.51; p < 0.001), and higher Breslow thickness (HR, 1.04; 95% CI, 1.01–1.09; p = 0.048) were associated with poorer RFS. In multivariable analysis, stage III disease (HR, 3.05; 95% CI, 1.52–6.11; p = 0.002) and low vitamin D level (HR, 2.61; 95% CI, 1.52–4.49; p < 0.001) remained independent predictors of inferior RFS. Conclusions: Baseline serum 25(OH)D was independently associated with RFS in resected stage II–III cutaneous melanoma. Lower vitamin D levels were linked to shorter RFS, suggesting that vitamin D status may provide complementary prognostic information in the postoperative setting. Prospective validation is warranted.

🔖

Cite This Article

Ekin, O., Butun, O., İzgör, R. B., Aktepe, O. H. (2026). Prognostic Value of Baseline Serum 25-Hydroxyvitamin D in High-Risk Resected Cutaneous Melanoma. Abant Tıp Dergisi, Cilt: 15 Sayı: 2, 165–173. https://doi.org/10.47493/abantmedj.1940302

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (28)

  1. Márquez-Rodas I, Muñoz Couselo E, Rodríguez Moreno JF, Arance Fernández AM, Berciano Guerrero MÁ, Campos Balea B, ve ark. SEOM-GEM clinical guidelines for cutaneous melanoma (2023). Clin Transl Oncol. 2024;26(11):2841-55.
  2. Helvind NM, Brinch-Møller Weitemeyer M, Chakera AH, Hendel HW, Ellebæk E, Svane IM, ve ark. Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021. JAMA Dermatol. 2023;159(11):1213-22.
  3. Roccuzzo G, Sarda C, Pala V, Ribero S, Quaglino P. Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios. Expert Rev Mol Diagn. 2024;24(5):379-92.
  4. Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, ve ark. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718-29.
  5. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, ve ark. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824-35.
  6. Eggermont AMM, Blank CU, Mandala M, Long G V, Atkinson VG, Dalle S, ve ark. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol. 2020;38(33):3925-36.
  7. Eggermont AMM, Blank CU, Mandala M, Long G V, Atkinson V, Dalle S, ve ark. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378(19):1789-801.
  8. Long G V, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, ve ark. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024;391(18):1709-20.
  9. Gallo D, Baci D, Kustrimovic N, Lanzo N, Patera B, Tanda ML, ve ark. How Does Vitamin D Affect Immune Cells Crosstalk in Autoimmune Diseases? Int J Mol Sci. 2023;24(5):4689.
  10. Bikle DD. Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. Chem Biol. 2014;21(3):319-29.
  11. Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, Vogt T, ve ark. Low Serum 25-Hydroxyvitamin D Concentrations Are Associated with Increased Risk for Melanoma and Unfavourable Prognosis. PLoS One. 2014;9(12):e112863.
  12. Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: A pilot study. Australas J Dermatol. 2018;59(3):182-7.
  13. Moro R, Sánchez-Silva A, Aguerralde-Martin M, González-Cuevas R, Peruilh-Bagolini L, Traves V, ve ark. Efecto de los niveles séricos de vitamina D en el pronóstico del melanoma cutáneo. Actas Dermosifiliogr. 2022;113(4):347-53.
  14. Befon A, Katoulis AC, Georgala S, Katsampas A, Chardalia V, Melpidou A, ve ark. Serum Total 25-Hydroxyvitamin D Levels in Patients With Cutaneous Malignant Melanoma: A Case-Control Study in a Low-Risk Southern European Population. Dermatol Pract Concept. 2019;10(1):e2020010.
  15. De Smedt J, Van Kelst S, Janssen L, Marasigan V, Boecxstaens V, Bogaerts K, ve ark. High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial). Br J Dermatol. 2024;191(6):886-96.
  16. Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, ve ark. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. Br J Cancer. 2018;119(7):793-800.
  17. Tas F, Erturk K, Oguz Soydinc H. Serum 25-Hydroxyvitamin D Level Is Not Associated with Duration and Activity of Disease in Melanoma Patients. Nutr Cancer. 2021;73(7):1126-9.
  18. Krist AH, Davidson KW, Mangione CM, Cabana M, Caughey AB, Davis EM, ve ark. Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(14):1436-42.
  19. Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, ve ark. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest. 2017;97(6):706-24.
  20. Muralidhar S, Filia A, Nsengimana J, Poźniak J, O'Shea SJ, Diaz JM, ve ark. Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity. Cancer Res. 2019;79(23):5986-98.
  21. Ben-Eltriki M, Gayle EJ, Paras JM, Nyame-Addo L, Chhabra M, Deb S. Vitamin D in Melanoma: Potential Role of Cytochrome P450 Enzymes. Life (Basel). 2024;14(4):510.
  22. Danielsson C, Fehsel K, Polly P, Carlberg C. Differential apoptotic response of human melanoma cells to 1α,25-dihydroxyvitamin D3 and its analogues. Cell Death Differ. 1998;5(11):946-52.
  23. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019;25(10):3074-83.
  24. Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50(4):1-14.
  25. Chatterjee M. Vitamin D and genomic stability. Mutat Res. 2001;475(1-2):69-87.
  26. Idorn LW, Philipsen PA, Wulf HC. Sun exposure before and after a diagnosis of cutaneous malignant melanoma: estimated by developments in serum vitamin D, skin pigmentation and interviews. Br J Dermatol. 2011;165(1):164-70.
  27. Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, ve ark. The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr. 2007;86(4):959-64.
  28. Bounas N, Seretis K. Vitamin D and Cutaneous Melanoma Risk: An Umbrella Review of Systematic Reviews and Meta-Analyses. Photobiomodul Photomed Laser Surg. 2024;42(4):249-66.